Medexus Pharmaceuticals (TSE:MDP) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Medexus Pharmaceuticals (TSE:MDP) had its target price boosted by equities researchers at Stifel Nicolaus from C$4.15 to C$4.50 in a research note issued on Tuesday,BayStreet.CA reports. Stifel Nicolaus’ target price points to a potential upside of 2.51% from the company’s previous close.

A number of other equities analysts have also issued reports on the stock. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a report on Monday, September 30th. Finally, Raymond James raised Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective for the company in a report on Wednesday, January 8th. Two analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, Medexus Pharmaceuticals presently has an average rating of “Strong Buy” and an average target price of C$5.58.

Medexus Pharmaceuticals Stock Performance

Shares of TSE MDP traded up C$0.14 during trading hours on Tuesday, hitting C$4.39. The stock had a trading volume of 45,478 shares, compared to its average volume of 95,070. The company has a market capitalization of C$107.69 million, a P/E ratio of 87.80 and a beta of 1.96. The firm’s 50-day moving average price is C$2.84 and its two-hundred day moving average price is C$2.57. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$4.40.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.